UPMC Ovarian Cancer Study

Cancer differentiation analysis technology as a novel technology for cerebral cancer screening.

In this retrospective, blinded validation study, a mixed cohort of at least 40 banked, frozen human serum samples, consisting of at least 20 samples from cancer free women (controls) and at least 20 samples from ovarian cancer patients (Stage I – IV), will be analyzed with Cancer Differentiation Analysis (CDA) technology for cellular and molecular signals of ovarian cancer. Specifically, this study aims to evaluate the sensitivity and specificity of CDA technology in ovarian cancer screening within a well-defined sample population.
Risk-assessment of all serum samples by Anpac will involve the evaluation of three parameters: Protein Tumor Factor (PTF), Cellular Tumor Factor (CTF), and an overall CDA value.

Details of the work:

1. Dr. Modugno will provide 1mL of frozen serum on each of at least 20 women diagnosed with ovarian cancer and at least 20 control women known to be cancer free at the time of serum collection. The serum samples will be shipped according to Anpac instruction to their lab in San Jose, California.
a. Anpac will pay the cost of shipping.
b. Samples will be labeled only with a study ID. No identifying information will ever be provided to Anpac.
c. The key linking study ID to patient name will be maintained by Dr. Modugno and her staff and will at no time be shared with Anpac or other study investigators at the University of Pittsburgh.
2. Within six months of receipt of the samples, Anpac will provide to Dr. Modugno with the data elements for each sample, including PTF, CTF and overall CDA values.
3. A member of Dr. Modugno’s study team will analyze the data.
a. A Receiver-operator curve (ROC) will be employed to evaluate the accuracy of CDA technology in ovarian cancer screening within the study population.
4. The resulting ROC will be provided back to Anpac

Participate

R&D investigations and formal clinical trials in the United States.

Additional Clinical Trials

iMarc Breast Cancer Research

Anpac Bio’s CDA, Cancer Differentiation Analysis, is a revolutionary technology.

Results speak.

26

Cancer types detected

525+

screened cases

85-90%

Accuracy rate

200k+

Test samples run to date

The science BEHIND cda technology

“game changing”

Read about our CDA technology at the Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.

Read the full article

Anpac is excited to be working with Dr. Levitt on our ground-breaking technology. Our innovative biophysical approach to cancer screening and detection is complementary with Dr. Levitt’s background in quantum mechanics, chemistry, and structural biology. We believe that Dr. Levitt’s contributions will help us to achieve further market penetration in China and will assist us in our entrance in the United States through clinical trials and additional academic collaborations.

ANPAC BIO APPOINTS NOBEL PRIZE WINNER DR. MICHAEL LEVITT AS CHIEF CONSULTANT TO LEAD ANPAC’S PIONEERING EFFORTS IN CANCER SCREENING

Read the full article

Quick Links

Contact Information

Anpac Technology USA (Anpac Bio)
3 Spring House Innovation Park, Suite 150
Ambler, PA 19002

Email: [email protected]

Phone Number: +1 (267) 810-6776

Anpac Bio-Medical Science Co., Ltd.

Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (Cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented Cancer Differentiation Analysis (CDA) technology and proprietary cancer-detection device.